Grassley C, Baucus M, Graham D, Singh G, Psaty B, Kweder S, Gilmartin R. 2004. FDA, Merck and Vioxx: Putting Patient Safety First? Statements at the November 18, 2004 hearing before the United States Senate Committee on Finance, United States Senate.

Henderson D. 2006 (February). Doc Room Stats for IOM. Personal Communication: E-mail to Stratton K (IOM Staff).

Hensley S, Davies P, Martinez B. 2005. Vioxx Verdict Stokes Backlash That Hit FDA, Manufacturers. [Online]. Available: http://online.wsj.com/article/0,,SB112467370587619279-email,00.html [accessed October 10, 2005].

Huddleston, RD. 1999. FDA Clinical Investigator Site Inspections: The Sponsor’s Role. [Online]. Available: http://www.findarticles.com/p/articles/mi_qa3899/is_199907/ai_n8868995/print [accessed August 1, 2006].

IOM (Institute of Medince). 2007. Preventing Medication Errors. Washington, DC: The National Academies Press.

Kaiser Family Foundation. 2005. Prescription Drug Trends. [Online]. Available: http://www.kff.org/insurance/upload/3057-04.pdf [accessed March 10, 2006].

Kaitin KI. 2005. Numbers of active investigators in FDA-regulated clinical trials drop. Tufts Center for the Study of Drug Development Impact Report 7(3).

Kennedy DL, Uhl K, Kweder SL. 2004. Pregnancy exposure registries. Drug Saf 27(4): 215-228.

Lasser KE, Seger DL, Yu DT, Karson AS, Fiskio JM, Seger AC, Shah NR, Gandhi TK, Rothschild JM, Bates, DW. 2006. Adherence to black box warnings for prescription medications in outpatients. Arch Int Med Feb(166):338-344.

Lipsky MS, Sharp LK. 2001. From idea to market: the drug approval process. J Am Board Fam Pract 14(5):362-367.

Lurie P, Woodcock J, Kaitin KI. 1999. FDA drug review: the debate over safety, efficacy, and speed. Medical Crossfire 1(3):52-60.

Meadows M. 2002. The FDA’s drug review process: ensuring drugs are safe and effective. FDA Consum 36(4):19-24.

Meadows M. 2003. Drug Research and Children. [Online]. Available: http://www.fda.gov/fdac/features/2003/103_drugs.html [accessed July 12, 2006].

Meyer R. 2004. Letter to Amgen Inc and Danagher P, March 8, 2004. [Online]. Available: http://www.fda.gov/cder/foi/appletter/2004/21688ltr.pdf [accessed August 28, 2006].

Moynihan R. 2002. FDA fails to reduce accessibility of paracetamol despite 450 deaths a year. BMJ 325(7366):678.

NCHS (National Center for Health Statistics). 2004. Health, United States, 2004: With Chart-book on Trends in the Health of Americans with Special Feature on Drugs. Hyattsville, MD: NCHS.

Neergaard L. 2005. FDA Looking into Blindness-Viagra Link. [Online]. Available: http://abc-news.go.com/Health/wireStory?id=796471 [accessed May 27, 2005].

NHLBI (National Heart, Lung and Blood Institute). 2005. Cardiac Arrhythmia Suppression Trial (CAST). [Online]. Available: http://www.clinicaltrials.gov/ct/show/NCT00000526 [accessed July 12, 2006].

Okie S. 2005. Safety in numbers—monitoring risk in approved drugs. N Engl J Med 352(12): 1173-1176.

PhRMA (Pharmaceutical Research and Manufacturers of America). 2006. Pharmaceutical Industry Profile. Washington, DC.

Public Health Newswire. 2006. Drugs’ Black Box Warning Violations in Outpatient Settings Putting Patients at Risk. [Online.] Available: http://www.medicalnewstoday.com/medicalnews.php?newsid=37735 [accessed July 13, 2006].

Racoosin JA. 2006 (January 17). Pre-Marketing Assessment of Drug Safety. PowerPoint presentation, presented at the Institute of Medicine Workshop on Advancing the Methods



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement